Mylan Draws Hope From FDA’s Fluticasone Labelling Update
Mylan sees supplemental labelling updates made by the FDA for all fluticasone-based medicines as
You may also be interested in...
Mylan has launched its Wixela Inhub rival to GSK’s Advair Diskus at a 70% discount to the brand price.
Mylan has revealed that its Wixela Inhub US rival to GSK’s Advair Diskus will be on the market by the end of February, acting quickly after their recent FDA approval.
Mylan believes that US Food and Drug Administration (FDA) approval of its Wixela Inhub generic alternative to GlaxoSmithKline’sAdvair Diskus (fluticasone/salmeterol) respiratory blockbuster is “imminent”. “Mylan confirms it has not received any new information request or complete response letter (CRL) from the FDA,” the company said in a statement issued on 22 October.